Download Now - The Burrill Report

More documents

Recommendations

Info

THIRD QUARTER STATISTICSThe Burrill Report❱❱ (continued)Q3 2012 Top Partnering DealsCOMPANY/LI-CENSEEOnconovaEvotec (Germany)AstraZeneca(United Kingdom)Rhizen Pharmaceuticals(Switzerland)Inspiration BiopharmaceuticalsCOMPANY/LICENSERBaxter InternationalJanssen Pharmaceuticals(J&J)TOTALDEALVALUE(USD M)UPFRONT(USD M)PRINCIPAL FO-CUS/ STAGE OFDEVELOPMENTRATIONALE/PRINCIPAL ASSET565.0 50 Cancer/ phase 3 Baxter and Onconova Therapeutics enter into a European licensingagreement for rigosertib, a novel targeted anti-cancer compoundcurrently in a phase 3 study for the treatment of a groupof rare hematologic malignancies and in a Phase 2/3 study forpancreatic cancer. Baxter will obtain commercialization rights inthe European Union and other countries in Europe for an upfrontpayment of $50 million plus up to $515 million in pre-commercialdevelopment and regulatory milestones for the two cancer indications,in addition to sales milestones and royalties. Baxter hasthe option to participate in the development and commercializationof rigosertib in additional indications.308.0 8 Insulin production/preclinicalPfizer 250.0 250 Gastrointestinal/marketedTG Therapeutics250.0 N/A Cancer; autoimmune/preclinicalIpsen (France) 215.0 30 Hemophilia/phase 3Evotec AG licenses to Janssen Pharmaceuticals a portfolio ofsmall molecules and biologics designed to trigger the regenerationof insulin-producing beta cells. Janssen will receive exclusiveaccess to a series of candidates designed to trigger the regenerationof insulin-producing beta cells. The small molecules andbiologics were identified by scientists in the Harvard Universitylaboratory of Douglas Melton, and further analyzed in collaborationwith scientists from Evotec, as part of the CureBeta researchand development program.Pfizer will acquire the exclusive global rights to market gastroesophagealreflux disease drug Nexium for the approved overthe-counterindications in the United States, Europe and the restof the world. Pfizer will make an upfront payment of $250 millionto AstraZeneca, and AstraZeneca is eligible to receive milestoneand royalty payments based on product launches and sales.Nexium, a proton pump inhibitor, was launched by AstraZenecain Europe in 2000 and the U.S. in 2001. AstraZeneca will continueto manufacture and market the prescription product, as well assupply Pfizer with the OTC product upon the receipt of regulatoryapproval.TG Therapeutics and Rhizen Pharmaceuticals have entered intoan exclusive global agreement to collaborate on the developmentand commercialization of Rhizen’s lead product candidate,a novel PI3K delta inhibitor, TGR-1202. The companies will jointlydevelop the product on a worldwide basis, excluding India,initially focusing on indications in the area of hematologic malignanciesand autoimmune disease. Beyond TGR-1202, Rhizenwould contribute backup molecules providing multiple opportunitiesfor TG to develop differentiated therapies against hematologiccancers and autoimmune diseases. TG Therapeutics will beresponsible for the costs of clinical development of the productsthrough phase 2, after which TG Therapeutics and Rhizen will bejointly responsible for all development costs of the product.Ipsen renegotiates its 2010 strategic partnership agreementwith Inspiration Biopharmaceuticals for the development andcommercialization of Inspiration’s recombinant product portfolio:OBI-1, a recombinant porcine factor VIII being developed for thetreatment of patients with acquired hemophilia A and congenitalhemophilia A with inhibitors, and IB1001, a recombinant factorIX for the treatment and prevention of bleeding in patients withhemophilia B. The new agreement aims to establish an effectivestructure whereby Ipsen gains commercial rights in key territories.Inspiration remains responsible for the world-wide developmentof OBI-1 and IB1001. As part of the renegotiation, Inspirationgets $30.0 million upfront, and is eligible for $185 million in additionalmilestones.nNovember 2012 20
THIRD QUARTER STATISTICSThe Burrill ReportQ3 2012 Select Pharma/Biotech Alliances With Academia And NonprofitsCOMPANY ACADEMIA/ NONPROFIT PRINCIPAL FOCUS TERMSADC Therapeutics(Switzerland)Cancer Research Technology(United Kingdom)Antibody drugconjugatesFluxion Biosciences Stanford University CancerpharmacogeneticsAstraZenecaCornell University; FeinsteinInstitute for Medical Research;University of British Columbia;Washington UniversityAlzheimer’s diseaseBoehringer Ingelheim Harvard University TranslationalresearchAbbott Laboratories;AstraZeneca; Bayer; EliLilly; GlaxoSmithKline;Merck; SanofiSanofi (France)Life TechnologiesBGI (China)Bill & Melinda GatesFoundation; InfectiousDisease Research Institute;National Institute of Allergyand Infectious Diseases; TexasA&M University; Weill CornellMedical CollegeBrigham and Women’sHospital (Harvard)Structural GenomicsConsortiumUniversity of Edinburgh(United Kingdom)TB researchaccelerationType 1 diabetesresearchEpigenetic antibodymaster listGenomicsCipla (India) Drugs for Neglected Diseases HIV anti-retroviraltherapyNovartis (Switzerland) University of Pennsylvania PersonalizedimmunotherapyCollaboration to develop cancer treatments called antibody drugconjugates using cancer research technology antibodies andpeptides, and ADC Therapeutic’s ‘warhead’ and linker chemistries.Partnership with Stanford’s School of Medicine to develop tests tosubtype different forms of disease and to develop more effective,individualized treatments for breast and lung cancer patients.Drug discovery partnership focused on apolipoprotein E (APOE)epsilon 4 in Alzheimer’s disease. The pharma’s neuroscienceinnovative medicines unit (iMED) will provide programmanagement and scientific expertise.Collaboration to identify signaling pathways and drug targetsfor cancer, cardiometabolic, fibrotic, and infectious diseases. Ajoint research committee will award funds to selected proposals.The collaboration is already supporting eight projects in cancerstem cell survival, replication of detrimental viruses, and fibroticprocesses.The seven pharmas have opened up sections of their compoundlibraries and agreed to share data with each other and the researchinstitutions under the Gates Foundation’s TB Drug Acceleratorprogram to discover treatments for tuberculosis.Research collaboration focused on immunology of type 1 diabeteswit both organizations sharing knowledge and applying theirrespective expertise in basic and applied research regardingdiabetes and drug target and candidate development. Researchersfrom both organizations will undertake proof-of-concept, safetyand functional studies for a novel immunomodulatory approachto treat type 1 diabetes. Sanofi has an option to exclusively licenseintellectual property emerging from this collaboration.Partnership to generate a first-ever master set of quality epigeneticrecombinant antibodies for use in disease-related research.Partners also include scientists at the Universities of Chicago andToronto.Partnership aimed at enhancing the university’s genomics andbioinformatics activities in biomedical research and livestockstudies.Partnership to develop by 2015 a low-cost, four-drug antiretroviralcombination therapy to treat HIV infection in children less thanthree years old.University of Pennsylvania grants Novartis an exclusive worldwidelicense to the technologies used in an ongoing trial of patientswith chronic lymphocytic leukemia as well as future cellularimmunotherapies using chimeric antigen receptor technologies.Penn and Novartis will build a first-of-its-kind Center for AdvancedCellular Therapies on the Penn campus in Philadelphia. Novartiswill invest in the establishment of the CACT and future research ofthe technology. Additional milestone and royalty payments to Pennare also part of the agreement.GNS Healthcare CHDI Foundation Neurology Data analytics company GNS Healthcare and CHDI will createa computer model of Huntington’s disease using GNS’ REFSmodeling technology with CHDI providing genomic, expression,and cell-signaling data. GNS will transfer the model to CHDI andaffiliated researchers after it is completed.(continued) ❱❱November 2012 21
Page 2 and 3: The Burrill ReportThe Burrill Repor
Page 5: The Burrill ReportThe Risk and Rewa
Page 10 and 11: The Burrill ReportTHIRD QUARTER STA
Page 12 and 13: THIRD QUARTER STATISTICSThe Burrill
Page 24 and 25: SEPTEMBER STATISTICSThe Burrill Rep
Page 28: SEPTEMBER STATISTICSThe Burrill Rep
Page 39 and 40: PIPELINEThe Burrill Report❱❱ (c
Page 45: PIPELINEThe Burrill Report❱❱ (c
Page 48 and 49: PIPELINEThe Burrill ReportUpcoming
Page 50 and 51: INDICESThe Burrill ReportBurrill Bi

Download Now - The Burrill Report

Create successful ePaper yourself

Delete template?

Save as template?